JAKAFI’s demand continues to grow in Polycythemia Vera
The therapeutic paradigm for polycythemia vera treatment has evolved notably in recent years. Historically managed with generics like aspirin, hydroxyurea, phlebotomy, and interferons, the landscape shifted dramatically with the FDA approval of JAKAFI (ruxolitinib) in 2014 as a second-line option. Developed by Incyte, JAKAFI remains a cornerstone in polycythemia vera treatment, particularly when hydroxyurea is ineffective or poorly tolerated. Another major advancement occurred in 2021 with the U.S. approval of BESREMi (ropeginterferon alfa-2b) as a first-line monotherapy for polycythemia vera. The ongoing BES...